Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3315151
Max Phase: Preclinical
Molecular Formula: C52H65N11O11S2
Molecular Weight: 1084.29
Molecule Type: Protein
Associated Items:
ID: ALA3315151
Max Phase: Preclinical
Molecular Formula: C52H65N11O11S2
Molecular Weight: 1084.29
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(C)[C@H](NC(=O)[C@@H]1CSSC(C)(C)[C@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCN)C(=O)N[C@@H](Cc2ccc(C#N)cc2)C(=O)N1)C(=O)O
Standard InChI: InChI=1S/C52H65N11O11S2/c1-28(2)42(51(73)74)62-49(71)40-27-75-76-52(3,4)43(63-44(66)34(55)24-41(64)65)50(72)60-38(21-29-11-6-5-7-12-29)46(68)59-39(23-32-26-56-35-14-9-8-13-33(32)35)48(70)57-36(15-10-20-53)45(67)58-37(47(69)61-40)22-30-16-18-31(25-54)19-17-30/h5-9,11-14,16-19,26,28,34,36-40,42-43,56H,10,15,20-24,27,53,55H2,1-4H3,(H,57,70)(H,58,67)(H,59,68)(H,60,72)(H,61,69)(H,62,71)(H,63,66)(H,64,65)(H,73,74)/t34-,36-,37-,38-,39+,40-,42-,43+/m0/s1
Standard InChI Key: HLGVBTPNJHCCTL-FGSBMQTASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1084.29 | Molecular Weight (Monoisotopic): 1083.4306 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Carotenuto A, Auriemma L, Merlino F, Yousif AM, Marasco D, Limatola A, Campiglia P, Gomez-Monterrey I, Santicioli P, Meini S, Maggi CA, Novellino E, Grieco P.. (2014) Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor., 57 (14): [PMID:24992374] [10.1021/jm500218x] |
Source(1):